bluebird bio

bluebird bio was established in April 1992 as Genetix Pharmaceuticals by MIT faculty members Philippe Leboulch and Irving London. The company initially pursued genetic medicines for severe inherited blood disorders, particularly beta-thalassemia and sickle cell disease. Its leading approach used a lentiviral vector to add a functional gene to a patient's hematopoietic stem cells. The modified cells could then generate blood cells capable of producing a therapeutic form of hemoglobin. Walter Ogier served as chief executive officer from 2001 to 2005, during a period when the business was focused on advancing Lentiglobin. A significant clinical milestone came in 2010, when investigators at Hospital Necker in Paris reported prolonged transfusion independence in a patient with severe beta-thalassemia who had received the therapy. Published results described the finding as an important demonstration of long-term correction of a major inherited disease through gene therapy. In September 2010, Genetix Pharmaceuticals changed its name to bluebird bio, and Nick Leschly became chief executive officer. The renamed company pursued clinical development in blood disorders while broadening its work to other genetic diseases and cancer immunotherapy. It completed an initial public offering in June 2013 and acquired Precision Genome Engineering in June 2014 for consideration reported as potentially reaching $156 million. The oncology strategy included a 2017 collaboration with Celgene, now part of Bristol Myers Squibb, around bb2121, a BCMA-directed CAR-T therapy. The program later became associated with idecabtagene vicleucel. In 2020, the FDA first issued a refusal-to-file letter concerning the marketing application and later accepted a revised application. bluebird bio also announced a 2018 collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialize new cell therapies for cancer. The company achieved its first major regulatory milestones in inherited diseases with Zynteglo and Skysona. The European Commission authorized Zynteglo in 2019 for transfusion-dependent beta-thalassemia. The therapy received United States approval in 2022, with orphan-drug and breakthrough-therapy designations for the relevant indication. Skysona was authorized in the European Union in 2021 for cerebral adrenoleukodystrophy. In November 2021, bluebird bio completed the corporate separation of its oncology business into 2seventy bio. In December 2023, the FDA approved Lyfgenia, the commercial name for lovotibeglogene autotemcel, for specified patients with sickle cell disease. The treatment became part of a new commercial model involving specialist manufacturing and administration as well as extended follow-up. bluebird bio announced outcomes-based contracts under which payer obligations could be reduced if defined vaso-occlusive outcomes occurred during a monitoring period. The company also reported reimbursement agreements covering approximately 200 million people in the United States. Commercialization remained difficult because individualized gene therapies require complex infrastructure and can carry very high one-time prices. Zynteglo attracted criticism because of its reported $1.8 million price. Lyfgenia was announced with a wholesale acquisition cost of $3.1 million, and its label includes a boxed warning about the potential risk of hematologic malignancy. These issues contributed to broader debate about access, reimbursement, long-term safety, and how health systems should pay for durable gene-therapy benefits. bluebird bio undertook workforce reductions in 2022 and 2024, each reported as affecting approximately one-quarter to three-tenths of employees. The supplied reference material further states that investment funds managed by The Carlyle Group and SK Capital Partners acquired the company in June 2025 and that the business subsequently rebranded as Genetix Biotherapeutics. The available material does not clarify whether bluebird bio continued as a separate operating brand or legal entity after that transaction.

1. 2025Acquisition and reported rebranding

   Reference material states that Carlyle- and SK Capital-managed funds acquired the company and that it later became Genetix Biotherapeutics.

   Source
2. 2023United States approval of Lyfgenia

   The FDA approved lovotibeglogene autotemcel for eligible patients with sickle cell disease.

   Source
3. 2022United States approval of Zynteglo

   The FDA approved Zynteglo for transfusion-dependent beta-thalassemia.

   Source
4. 2021European authorization of Skysona

   The European Commission authorized elivaldogene autotemcel for cerebral adrenoleukodystrophy.

   Source
5. 20212seventy bio spin-off

   bluebird bio completed the separation of its oncology-focused business into 2seventy bio.

   Source
6. 2019European authorization of Zynteglo

   The European Commission authorized betibeglogene autotemcel for transfusion-dependent beta-thalassemia.

   Source
7. 2014Precision Genome Engineering acquisition

   The company acquired Precision Genome Engineering in a transaction reported as worth up to $156 million.

   Source
8. 2013Initial public offering

   bluebird bio became a public company through an offering that raised $116 million.

   Source
9. 2010Company adopts the bluebird bio name

   Genetix Pharmaceuticals was renamed bluebird bio, with Nick Leschly appointed chief executive officer.

   Source
10. 2010Long-term beta-thalassemia result is reported

    Nature published results describing prolonged transfusion independence after Lentiglobin treatment in a patient with severe beta-thalassemia.

    Source
11. 1992Genetix Pharmaceuticals is founded

    Philippe Leboulch and Irving London founded the company in April as Genetix Pharmaceuticals.

    Source

Specialist developer and commercializer of high-complexity gene therapies for severe inherited diseases, with additional experience in engineered cellular immunotherapies.

• ZyntegloGene therapy2019

  Zynteglo is the brand name for betibeglogene autotemcel, an autologous lentiviral gene therapy for transfusion-dependent beta-thalassemia. A patient's blood-forming stem cells are collected, genetically modified to support production of functional beta-globin, and reinfused after conditioning treatment. It received European authorization in 2019 and United States FDA approval in 2022. Its high one-time price has made it a prominent example in discussions about gene-therapy affordability and reimbursement.

• SkysonaGene therapy2021

  Skysona is the brand name for elivaldogene autotemcel, an autologous gene therapy developed for cerebral adrenoleukodystrophy, a severe inherited disorder that can damage the brain's white matter. The product uses a patient's own genetically modified hematopoietic stem cells. The European Commission authorized it in 2021. Its development expanded bluebird bio's lentiviral platform beyond inherited blood disorders.

• LyfgeniaGene therapy2023

  Lyfgenia is the commercial name for lovotibeglogene autotemcel, an autologous gene therapy for patients aged 12 and older with sickle cell disease and a history of vaso-occlusive events. The FDA approved it in December 2023. The treatment is administered through a complex cell-collection and manufacturing process and requires long-term follow-up. Its United States label includes a boxed warning concerning the potential risk of hematologic malignancy.

• LentiGlobinGene-therapy platform and product candidate

  LentiGlobin was the company's principal lentiviral gene-therapy program during its early development history. It was studied for severe inherited blood disorders, including beta-thalassemia and sickle cell disease, and served as the foundation for later commercial products such as Zynteglo and Lyfgenia.

• 2025Acquisition by investment funds and reported rebrandingM&A

  The company underwent restructuring and workforce reductions while commercializing high-cost individualized gene therapies.

  What changed. Reference material states that funds managed by The Carlyle Group and SK Capital Partners acquired the company and subsequently rebranded it as Genetix Biotherapeutics.

  Aftermath. The continuing legal and operating status of the bluebird bio brand is not clear from the supplied references.

  Source
• 2023Commercialize Lyfgenia with outcomes-based reimbursementProduct launch

  Lyfgenia's one-time treatment cost and complex administration created substantial reimbursement and affordability challenges.

  What changed. After FDA approval, bluebird bio introduced outcomes-based contracts with a monitoring period during which payer obligations could be reduced if specified sickle-cell-related hospitalizations occurred.

  Aftermath. The company reported two reimbursement agreements covering approximately 200 million people in the United States.

  Announced wholesale acquisition cost for Lyfgenia. $3.1 million (2023)

  Source
• 2021Separate oncology operations into 2seventy bioStrategy

  The company had developed oncology cell-therapy programs alongside its inherited-disease gene-therapy portfolio.

  What changed. bluebird bio completed a corporate spin-off that created 2seventy bio as an oncology-focused company.

  Aftermath. The transaction left bluebird bio more concentrated on gene therapies for inherited diseases.

  Source
• 2010Rebrand as bluebird bioStrategy

  Genetix Pharmaceuticals was developing lentiviral therapies for severe inherited diseases and sought a broader identity for its growth and clinical-stage business.

  What changed. The company changed its name to bluebird bio and appointed Nick Leschly as chief executive officer.

  Aftermath. The new identity preceded the company's public offering, expanded partnerships, and later commercialization of gene therapies.

  Source

• 2019Criticism of Zynteglo pricingControversy

  Zynteglo attracted criticism because its reported $1.8 million price placed it among the world's most expensive medicines, intensifying debate about access to one-time gene therapies and the allocation of payment over time.

  Source

• 2025Investment funds acquire bluebird bio and the business is rebranded

  Reference material states that funds managed by The Carlyle Group and SK Capital Partners acquired the company and that it subsequently adopted the Genetix Biotherapeutics name.

  M&A
  Source
• 2023Lyfgenia receives FDA approval for sickle cell disease

  The FDA approved lovotibeglogene autotemcel for eligible patients aged 12 and older with sickle cell disease and a history of vaso-occlusive events.

  Product launchRegulation
  Source
• 2021bluebird bio completes spin-off of 2seventy bio

  The company separated its oncology-focused operations into 2seventy bio.

  M&A
  Source
• 2020FDA accepts ide-cel application after earlier refusal to file

  Following an earlier refusal to file, the FDA accepted the marketing application for idecabtagene vicleucel and assigned a March 2021 action date.

  RegulationProduct launch
  Source
• 2013bluebird bio completes initial public offering

  The company became publicly traded in an offering that raised $116 million.

  Other
  Source
• 2010bluebird bio changes name from Genetix Pharmaceuticals

  The company adopted the bluebird bio name as it advanced its Lentiglobin gene-therapy program.

  OtherLeadership change
  Source

1. Bluebird bio
2. Bluebird bio official website